Vmbook Online ordering

Array Biopharma Inc

Array Biopharma Inc. is a publicly traded biotechnology company listed on the Nasdaq stock exchange under the ticker symbol ARRY. Below are some general details regarding the company's performance, financials, and growth prospects:

* Stock Performance: As of August 2022, Array Biopharma's stock price has been volatile, with fluctuations influenced by factors such as clinical trial results, regulatory updates, and market sentiment. The company's shares have experienced significant fluctuations, with a 52-week high of $46.95 and a low of $24.35.

* Market Capitalization: As of August 2022, Array Biopharma has a market capitalization of around $11.7 billion, classifying it as a small-cap company.

* Revenue and Earnings: Array Biopharma's revenue primarily stems from partnerships and licensing agreements. In 2020, the company reported a net loss of $43.9 million, or $0.48 per share, compared to a net loss of $41.1 million, or $0.50 per share, in the previous year. The company's revenue has increased, mainly due to its partnership with Roche and Genentech.

* Growth Prospects: The company focuses on developing innovative therapies for cancer and autoimmune diseases. Its lead product candidate, encorafenib, is being studied in combination with binimetinib for advanced melanoma treatment. Array Biopharma is also exploring other pipeline products, such as ARRY-797 and selinexor. Positive clinical trial results and significant growth potential in the cancer therapy market could contribute to the company's growth prospects.

* Financials: The company's financial performance has been mixed. In the second quarter of 2022, Array Biopharma reported a net loss of $43.0 million or $0.38 per share, whereas its collaboration revenue totaled $27.4 million.

It's important to remember that investing in the stock market includes risks, and investors should do their studies and seek financial advice to make well-informed decisions.